The publisher of TON is pleased to present an exclusive podcast providing peer-to-peer nursing perspectives on the current role of T-cell–redirecting bispecific antibodies, a new drug class targeting novel cancer antigens in patients with relapsed or refractory multiple myeloma (MM), and introducing talquetamab, a member of this drug class that binds GPRC5D expressed on malignant plasmacytes.

The publishers of JHOP and TON are pleased to present an exclusive podcast providing peer-to-peer nursing perspectives on the current role of immunotherapy in patients with advanced multiple myeloma (MM) and introducing a new class of agents: T-cell–redirecting bispecific antibodies (Tcr-bsAbs).


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: